- Canada doing away with door-to-door mail delivery by 2018
- NSA chief defends phone spying: ‘There is no other way’
- Hawaii Health Department head killed in plane crash
- Colorado school drops sexual harassment label on boy who kissed girl’s hand
- Australia court strikes down 5-day-old, gay-marriage law
- Fake interpreter at Mandela service: ‘Sorry,’ I have schizophrenia
- George Zimmerman will not be charged in domestic dispute
- Russian officials press bilateral U.S. trade deal
- Creator of ‘Selfies at Funerals’ blog retires after Obama flub: ‘Our work here is done’
- New Obama adviser Podesta is against Keystone but will steer clear of pipeline deliberations
By Matt Kibbe
The short-term deal will assure long-term overspending
Independent voices from the The Washington Times Communities
Topic - Abbott Laboratories Inc.
A health care company that illegally misbranded a drug approved to treat seizures, mania and migraines as one that would control aggression in elderly patients and treat schizophrenia will pay $1.5 billion in civil and criminal penalties, federal officials and Virginia Attorney General Kenneth T. Cuccinelli II announced Monday.
Drug and medical device firm Abbott Laboratories said Friday it has abandoned plans to sell its vaccines unit, less than three months after exploring sales talks with rival companies.